StockData
PharmaCyte Biotech, Inc. logo

PharmaCyte Biotech, Inc. (PMCB) stock

PMCBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 14, 2026Score 7/30
$5.37−0.05 (-0.92%)

Close on Nov 18, 2026Market cap $57.65MP/E –Yield –

PharmaCyte Biotech gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

PharmaCyte Biotech's gross profit for the twelve months ending Apr 30, 2017 was $0. For fiscal 2016 it was $0. The highest annual figure on record is $93.89K in fiscal 2011.

Annual gross profit

PeriodPeriod endValueChange
FY2016Apr 30, 2016$0–
FY2015Apr 30, 2015$0–
FY2014Apr 30, 2014$0-100.0%
FY2013Apr 30, 2013$2.54K-94.6%
FY2012Apr 30, 2012$47.18K-49.8%
FY2011Apr 30, 2011$93.89K–

Quarterly gross profit

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2017CQ1 2017Apr 30, 2017$0–
Q3 FY2017CQ4 2016Jan 31, 2017$0–
Q2 FY2017CQ3 2016Oct 31, 2016$0–
Q1 FY2017CQ2 2016Jul 31, 2016$0–

More PharmaCyte Biotech figures

See a number that looks wrong?